Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

230 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.
Hartwell MJ, Özbek U, Holler E, Renteria AS, Major-Monfried H, Reddy P, Aziz M, Hogan WJ, Ayuk F, Efebera YA, Hexner EO, Bunworasate U, Qayed M, Ordemann R, Wölfl M, Mielke S, Pawarode A, Chen YB, Devine S, Harris AC, Jagasia M, Kitko CL, Litzow MR, Kröger N, Locatelli F, Morales G, Nakamura R, Reshef R, Rösler W, Weber D, Wudhikarn K, Yanik GA, Levine JE, Ferrara JL. Hartwell MJ, et al. Among authors: ayuk f. JCI Insight. 2017 Feb 9;2(3):e89798. doi: 10.1172/jci.insight.89798. JCI Insight. 2017. PMID: 28194439 Free PMC article.
In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors.
Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Rischewski J, Sonnenberg S, Ayuk F, Tögel F, Schade U, Fiegel H, Erttmann R, Löliger C, Zander AR. Kröger N, et al. Among authors: ayuk f. Bone Marrow Transplant. 2002 Apr;29(8):683-9. doi: 10.1038/sj.bmt.1703530. Bone Marrow Transplant. 2002. PMID: 12180114
Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality.
Kröger N, Sayer HG, Schwerdtfeger R, Kiehl M, Nagler A, Renges H, Zabelina T, Fehse B, Ayuk F, Wittkowsky G, Schmitz N, Zander AR. Kröger N, et al. Among authors: ayuk f. Blood. 2002 Dec 1;100(12):3919-24. doi: 10.1182/blood-2002-04-1150. Epub 2002 Aug 8. Blood. 2002. PMID: 12393448 Free article. Clinical Trial.
Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin.
Kröger N, Zabelina T, Renges H, Krüger W, Kordes U, Rischewski J, Schrum J, Horstmann M, Ayuk F, Erttmann R, Kabisch H, Zander AR. Kröger N, et al. Among authors: ayuk f. Ann Hematol. 2002 Nov;81(11):627-31. doi: 10.1007/s00277-002-0566-0. Epub 2002 Nov 9. Ann Hematol. 2002. PMID: 12454700 Clinical Trial.
Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM).
Kröger N, Einsele H, Wolff D, Casper J, Freund M, Derigs G, Wandt H, Schäfer-Eckart K, Wittkowsky G, Schmitz N, Krüger W, Zabelina T, Renges H, Ayuk F, Krüll A, Zander A; German Study-group Multiple Myeloma (DSMM). Kröger N, et al. Among authors: ayuk f. Bone Marrow Transplant. 2003 Jun;31(11):973-9. doi: 10.1038/sj.bmt.1704049. Bone Marrow Transplant. 2003. PMID: 12774047 Clinical Trial.
Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
Kröger N, Perez-Simon JA, Myint H, Klingemann H, Shimoni A, Nagler A, Martino R, Alegre A, Tomas JF, Schwerdtfeger R, Kiehl M, Fauser A, Sayer HG, Leon A, Beyer J, Zabelina T, Ayuk F, San Miguel JF, Brand R, Zander AR. Kröger N, et al. Among authors: ayuk f. Biol Blood Marrow Transplant. 2004 Oct;10(10):698-708. doi: 10.1016/j.bbmt.2004.06.002. Biol Blood Marrow Transplant. 2004. PMID: 15389436 Free article. Clinical Trial.
Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning.
Shimoni A, Kröger N, Zabelina T, Ayuk F, Hardan I, Yeshurun M, Shem-Tov N, Avigdor A, Ben-Bassat I, Zander AR, Nagler A. Shimoni A, et al. Among authors: ayuk f. Leukemia. 2005 Jan;19(1):7-12. doi: 10.1038/sj.leu.2403591. Leukemia. 2005. PMID: 15526016
230 results